FEB 20, 2017 08:00 AM PST

CRISPR-Cas9: From reagent selection to experimental optimization

5 1 144

  • Product Manager; Dharmacon, part of GE Healthcare
      James Goldmeyer, PhD, Product Manager at Dharmacon, part of GE Healthcare. James joined Dharmacon in 2009 and has lead the development and commercial launch of numerous genome-wide shRNA and gene-overexpression product lines. He also shares responsibility for, and is heavily involved in the development, of the Dharmacon Edit-R Dharmacon Gene Engineering portfolio; with emphasis on the vector-based products for lentiviral sgRNA and Cas9 nuclease expression. James works closely with an expert group of R&D scientists on innovative tools and services for gene modulation and engineering. James earned a doctorate degree in physiology and neurobiology at the University of Connecticut.


    The use of CRISPR-Cas9 for gene editing has opened up many new avenues for scientific exploration around gene function. The rapid expansion of the field has led to a wide range of technology formats for use in both gene knockout and precision knockin genome engineering experiments. The seemingly ever-increasing toolset has also led to a widening knowledge gap for newcomers to the field to overcome in determining the proper reagents for performing experiments.

    During this webinar we will discuss the basics of CRISPR-Cas9 gene editing and the key criteria and decision points in selecting reagents based on your desired application. We will review all types of guide RNA and Cas9 nuclease formats and discuss the advantages and disadvantages of each.

    Furthermore, we will present techniques for optimizing experimental conditions to maximize success, including functional knockout and HDR for knockin. To provide context for the selection of different formats, we will present data showing direct comparison of Cas9 nuclease and guide RNA formats under different experimental protocols.

    Show Resources
    Loading Comments...